JPM vs MCI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MCI presents a contradictory profile with a stable Piotroski F-Score of 6/9 and a Graham Number of $22.64, yet it is plagued by severe fundamental decay. While the balance sheet remains healthy with low debt (D/E 0.22), the company is experiencing a sharp contraction in both revenue (-20.70%) and earnings (-21.40%). Most critically, the 9.14% dividend is unsustainable with a payout ratio of 116.79%, indicating the company is returning more capital than it generates. The combination of negative growth and a 0/100 technical trend suggests a value trap scenario.
Compare Another Pair
Related Comparisons
JPM vs MCI: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Barings Corporate Investors (MCI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.